Search
Ozanimod is mainly used in the treatment of multiple sclerosis, ulcerative colitis and Crohn's disease.
Ozanimod is a sphingosine-1-phosphate receptor 1 (S1P1) and S1P5 agonist. It induces GTPγS binding in cell membranes expressing human S1P1 or S1P5 (EC50s = 0.41 and 11 nM, respectively) but not cell membranes expressing S1P2 or S1P3 receptors (EC50s = >10,000 nM for both). Ozanimod (0.2 mg/kg) reduces the number of peripheral lymphocytes in rats. It reduces disease severity and the number of circulating lymphocytes in a mouse model of experimental autoimmune encephalomyelitis (EAE). Ozanimod (0.3 and 1 mg/kg) reduces disease severity and body weight loss in a mouse model of TNBS-induced colitis. Formulations containing ozanimod have been used in the treatment of relapsing multiple sclerosis and ulcerative colitis.
| Items | Specifications | Results |
| Appearance | White powder | Conforms |
| Assay | ≥95% | 95.83% |
| Product parameters | |
| Cas number: | 1306760-87-1 |
| Appearance: | White powder |
| Purity: | 95%min |
| Package details: | 50g/bottle; 1kg/foil bag |
| Brand: | Fortunachem |

Used as an autoimmune disease agent.

Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
English
Español
français
العربية